Abstract
Each year, about 900,000 persons are diagnosed with hepatocellular carcinoma (HCC) worldwide, making HCC the fifth most frequent incident cancer in men (69.8% of all HCC are in men) and the ninth in women. HCC incidence rates vary greatly according to geographic areas: 72.5% of all cases are registered in Asia, with 11.6 new cases per year every 100,000 inhabitants. In the United States and Europe, HCC is less common, with 5.2 new yearly cases per 100,000 individuals. A total of 830,000 persons die because of HCC each year (HCC is the third cause of oncological deaths), and the combination of HCC incidence and mortality rates results in 995,000 people living with HCC worldwide. Most of these “prevalent” cases are males (69.8%), and from Asia (73.6%). According to data collected from 107 European cancer registries for more than 10 million cancer patients, the EUROCARE study estimated in 12% the 5-year survival for all European HCC patients—an estimate lower than the one from the US (i.e., 20.3%). With regard to risk factors, it is worth stressing that infection with hepatitis B virus or hepatitis C virus are the most frequent causes of HCC, followed by alcohol consumption.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
Keywords
1 Incidence and Mortality
The World Health Organization (WHO) estimates that, worldwide, approximately 900,000 individuals develop each year hepatocellular carcinoma (HCC), the most common form of liver cancer [1]. Overall, 69.8% of all HCC cases occur in males, with a male-to-female ratio of 2.66. Accordingly, HCC is the fifth most frequent incident cancer type in men, the ninth in women, and the sixth in the two sexes combined (Table 1.1). From a geographical perspective, the incidence of HCC shows very wide variations. According to the Global Cancer Observatory (GCO), part of the International Agency for Research on Cancer (IARC), 72.5% of all new cases of HCC occur in Asia, where standardized incidence rates peak to 11.6 cases per 100,000 inhabitants/year. In Africa, HCC is the fourth most common incident cancer, with an 8.8 standardized yearly incidence rate of new cases per 100,000 individuals (Table 1.1). In Oceania, Northern America, and Europe, HCC is less common than in Asia or Africa, with the lowest incidence rate being documented in Europe (5.2 new cases per 100,000 individuals per year) where HCC ranks thirteenth overall among incident cancer types.
With regard to mortality, HCC is, worldwide, the third most common oncological cause of death: more than 830,000 persons die because of HCC every year. Most of these deaths (69.6%) occur among males, with a peak in mortality rates of 12.9 deaths per 100,000 people per year: HCC is the second cause of oncological deaths in males and the sixth among females (Table 1.1). Deaths caused by HCC are particularly frequent in Asia, where HCC is the second cause of cancer death. HCC mortality is also very frequent in Africa, with a mortality rate of 8.5 deaths per year per 100,000 individuals (HCC is the third cause of oncological deaths in the continent), whereas it is less common in Oceania, Northern America, and Europe, where HCC ranks seventeenth among oncological death causes, with a mortality rate (8.5 deaths per year per 100,000 individuals) 2.4 times lower than that registered in Asia (Table 1.1).
2 Prevalence
Prevalence is a statistical parameter that indicates the number of people living, in a specific geographic area and period, after a cancer diagnosis dating back one or more years. The prevalence of cancer patients is strictly related to the frequency (i.e., incidence) and the prognosis (i.e., survival) of the disease, and, to a lesser extent, to various factors like population aging, time trends in cancer incidence and survival [2]. In general, about 5% of the population is living after a diagnosis of all cancer types combined. The number of prevalent cases has increased at an annual mean rate of approximately 3%, an increase largely attributable to long-term survivorship of patients with cancers like, among others, breast, prostate and colon-rectum carcinomas [2,3,4]. Worldwide, it is estimated that 995,000 people are living after a diagnosis of HCC, i.e., 12.8 cases per 100,000 individuals. Most of these prevalent cases are males (69.8%) and from Asia (73.6%) while the proportion ranges from 6.1/100,000 in Latin America and the Caribbean to 15.8/100,000 in Asia (Table 1.1).
Long-term prevalence has been used as a surrogate for cancer cure, denoting disease-free survivors with mortality patterns resembling those of a population group without cancer of the same sex and age. Patients living after a cancer diagnosis include individuals under treatment, relapse-free ones at excess risk of recurrence or death, and patients who have the same death rate as the corresponding general population—they also represent the so-called “cured cancer patients” [5]. For European cancer patients diagnosed in 2000, the cure fraction widely varies according to cancer type and sex. Among men, the cure fraction ranges from 94% of those with testicular cancer to 4% of men with pancreatic carcinoma while, among women, it ranges from 87% for thyroid cancer to 5% for pancreatic cancer. Prevalent cancer patients with HCC show the second lowest cure fraction, i.e., 5% among men and 7% among women [6].
3 Survival of Patients Diagnosed with Hepatocellular Carcinoma
Overall, HCC is the second most lethal tumor after pancreatic cancer. In the United States, data from population-based cancer registries collected by the Surveillance, Epidemiology and End Results (SEER) Program estimated a 20.3% 5-year relative survival for people diagnosed with HCC. Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer after excluding the risk of dying from other causes [7]. No difference emerged in survival rates at each time interval between men and women.
Survival substantially depends on cancer stage at diagnosis, which determines treatment options and has a strong influence on the length of survival. In general, a cancer is deemed localized when it is found only in the part of the body where it started (also called stage 1 cancer). If a cancer has spread to a different part of the body, the stage is deemed regional or distant. The earlier HCC is discovered, the better is the chance of a person surviving five years after being diagnosed. Table 1.2 shows the distribution of liver cancer cases according to stage of disease at diagnosis, and the corresponding relative survival probability. In the United States, 45% of HCC are diagnosed at local stage, 26% at regional stage, and 18% at distant stage; the corresponding percentages of 5-year relative survival range from 35.3% to 2.7%.
At a population level, in Europe the survival probability of cancer patients has been evaluated by EUROCARE—a large cooperative study of population-based cancer survival. Overall, the results from EUROCARE indicates that cancer survival is improving over time although differences among countries persist. EUROCARE data from 107 cancer registries for more than 10 million cancer patients diagnosed up to 2007, and followed up to 2008, have shown that 5-year relative survival generally increased steadily over time for all European regions. However, improvements in survival for liver cancer and other rapidly fatal cancers (e.g., esophagus, pancreas, and pleura) were limited. For liver cancer, 5-year survival was approximately 12% [8].
Similarly, population-based survival probabilities for patients with liver cancer have been documented for England by the Cancer Research UK [9] for the period 2013–2017. As shown in Table 1.3, 38.1% of patients survived one year after diagnosis—a percentage drastically reduced to 12.7% after 5 years. It is worth stressing the substantial survival advantage of women as compared to men (13.7% vs. 10.7% at 5-year survival).
In Italy, the relative 5-year survival of Italian patients with liver cancer appears to be higher than the European average, i.e., 20%, without significant differences between men (20–21%) and women (19–22%), or among geographic areas. Interestingly, HCC patients who survive one year after diagnosis show a 33% probability of surviving an additional five years [10].
4 Main Risk Factors for Hepatocellular Carcinoma
The types and distribution of risk factors largely reflect the wide geographic variations documented in incidence and mortality rates across countries, and the higher frequency of HCC in men as compared to women.
Most HCC cases occur in individuals with a pre-existing liver disease, in particular liver cirrhosis or fatty liver disease. Worldwide, infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) are the most frequent causes of HCC [11]. With regard to HBV infection, it should be stressed that in high endemic areas—i.e., in Asia or in some sub-Saharan African countries—about 8% of individuals are chronically infected, and approximately 80% of HCC cases are recorded in people who are HBsAg-positive [12]. In contrast, HCV infection is the predominant risk factor for HCC in the USA, North America, Europe, and Japan [9], especially in HCV-infected patients with advanced fibrosis. Maucort-Boulch et al. [13] used data on the prevalence of HBV and HCV infection among 119,000 people with HCC from 50 countries worldwide to extrapolate data to countries without prevalence data. Globally, they estimated that 56% of the 770,000 cases of HCC that were recorded worldwide in 2012 were attributable to HBV and 20% to HCV. HBV is thought to be the cause of two out of three cases of HCC in less developed countries, and of one in four cases in more developed countries [13]. Antiviral therapies are effective in reducing the incidence of HCC, but do not eradicate the risk. Among patients with HCV infection who have a sustained virologic response to interferon-based treatment regimens, the risk of HCC is reduced from 6.2% to 1.5%, as compared with patients who do not have a response [14]. Promising results are progressively emerging from the use of direct-acting antivirals to treat and cure HCV infections, which are associated not only with a reduced mortality but also with a decreased risk of HCC development [15].
Alcoholic cirrhosis is the second most important risk factor for HCC in Europe and North America, the USA included. Alcoholic liver disease negatively impacts on liver metabolism and the risk of HCC increases with duration and quantity of alcohol consumption, starting from very low doses (<10 g/day). A statistically significant increased risk of 4% (from 2% to 6%) for every 10 g/day of alcoholic beverages has been estimated by the World Cancer Research Fund [16]. It is worthy of note that the alcohol-related risk of developing HCC substantially increases in association with several conditions, including HBV or HCV infection, older age, and obesity [17]. Smoking and coinfection with the human immunodeficiency virus can also contribute to the development of HCC.
5 Conclusion
Epidemiological data on HCC are an important tool to set priorities for liver cancer prevention. High-coverage of HBV vaccination will be transformational in HBV-endemic countries, but the prevention of HCV transmission and the treatment of chronic carriers of both viruses require actions toward new scalable solutions. In western countries, the reduction of alcohol consumption remains an essential step for HCC prevention.
References
International Agency for Research on Cancer/World Health Organization. Global Cancer Observatory. Cancer Today: Data visualization tools for exploring the global cancer burden in 2020. http://gco.iarc.fr/today. Accessed 16 Dec 2021.
Guzzinati S, Virdone S, De Angelis R, et al. Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020. BMC Cancer. 2018;18(19):169. https://doi.org/10.1186/s12885-018-4053-y.
Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer. 2012;107(7):1195–202.
Colonna M, Boussari O, Cowppli-Bony A, et al. Time trends and short term projections of cancer prevalence in France. Cancer Epidemiol. 2018;56:97–105. Erratum in: Cancer Epidemiol. 2018;57:158–9
Dal Maso L, Guzzinati S, Buzzoni C, et al. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol. 2014;25(11):2251–60.
Dal Maso L, Panato C, Tavilla A, et al. Cancer cure for 32 cancer types: results from the EUROCARE-5 study. Int J Epidemiol. 2020;49(5):1517–25.
NIH National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. https://seer.cancer.gov. Accessed 16 Dec 2021.
De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol. 2014;15(1):23–34.
Cancer Research UK. https://www.cancerresearchuk.org. Accessed 16 Dec 2021.
AIRTUM Working Group. Italian cancer figures - report 2016: survival of cancer patients in Italy. Epidemiol Prev. 2017;41(Suppl 1):96–9.
Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448–58.
Franco E, Bagnato B, Marino MG, et al. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol. 2012;4(3):74–80.
Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471–7.
Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329–37.
Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453–64.
World Cancer Research Fund International/American Institute for Cancer Research. Diet, nutrition, physical activity and liver cancer. 2015 (rev. 2018). https://www.wcrf.org/wp-content/uploads/2021/02/liver-cancer-report.pdf. Accessed 16 Dec 2021.
Loomba R, Yang HI, Su J, et al. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol. 2010;8(10):891–8.e1–2.
Acknowledgements
We thank Ms. Ilaria Calderan and Ms. Luigina Mei for editorial assistance. Studies on liver cancer are supported by Ricerca Corrente, Italian Ministry of Health, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits any noncommercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if you modified the licensed material. You do not have permission under this license to share adapted material derived from this chapter or parts of it.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2023 The Author(s)
About this chapter
Cite this chapter
Serraino, D., Fratino, L., Piselli, P. (2023). Epidemiological Aspects of Hepatocellular Carcinoma. In: Ettorre, G.M. (eds) Hepatocellular Carcinoma. Updates in Surgery. Springer, Cham. https://doi.org/10.1007/978-3-031-09371-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-031-09371-5_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-09370-8
Online ISBN: 978-3-031-09371-5
eBook Packages: MedicineMedicine (R0)